Skip to content
GLOBALANCE INTELLIGENCEThe economy ahead.
This Week Index 28/100 Sign in
Money & Investments › GI 100 Index
The Great Value ShiftInvestment ThemesGI 100 IndexGI PortfolioStart Future Check
AI FOOTPRINTsolidASSESSMENT 2026GLOBALANCEINTELLIGENCE
Globalance AI Footprint

Assessment as of November 2026 · next assessment 2027.

Result of the assessment by the Globalance research team under the published methodology. Not a certification or quality label.

How we assess ›

How this rating is builtVideo · 0:52
GI 100 Index · Profile

Eli Lilly and Co

USAAdoptersAssignment FullData quality Medium

Key messagesolid AI Footprint

Eli Lilly has a group-wide rule with prior approval for the use of artificial intelligence, oversight by the board and an audited information security programme, but discloses few figures, external audits or details on the limits of its own models. No harm caused by Lilly's AI is documented for the period; a law firm's inquiry into the sharing of usage data on the patient platform LillyDirect remains open.

Opportunities

  • Responsibilitysolid

    Board oversight of AI is documented in the 2024 to 2026 proxy statements (full board with regular updates, audit committee for AI-related risks, science and technology committee for AI in research) (S05, S06, S07, S01); the named executives are the CIDO and the Chief AI Officer (S01, S08).

    Board oversight of AI is documented in the 2024 to 2026 proxy statements (full board with regular updates, audit committee for AI-related risks, science and technology committee for AI in research) (S05, S06, S07, S01); the named executives are the CIDO and the Chief AI Officer (S01, S08). Since 2024 the group-wide procedure «Using AI Responsibly» has applied, with prior approval, a cross-functional review team, risk impact assessments and supplier clauses (S01). Metrics, AI-specific training records, external audits or certifications are missing; the only grievance channel is the general reporting line (S20). Hence solid, not strong.

  • Safetysolid

    The cybersecurity programme described in the 10-K is concrete (NIST CSF, external auditors, maturity assessments, threat simulations, incident response playbook, supplier review, audit committee oversight with CISO and Chief Privacy Officer) (S03, S04); for TuneLab the federated architecture with …

    The cybersecurity programme described in the 10-K is concrete (NIST CSF, external auditors, maturity assessments, threat simulations, incident response playbook, supplier review, audit committee oversight with CISO and Chief Privacy Officer) (S03, S04); for TuneLab the federated architecture with encrypted model updates is documented (S15). AI-specific evidence of reliability and validation exists only as self-description (LillyPod operated on premises and disconnected from the network, logging, model registry, inventory still being built) (S10, S11, S23). No AI-related incident is documented for the period; a law firm's inquiry into tracking pixels on LillyDirect remains open (S32). Solid with need for review, because the grade B evidence mainly concerns the general cyber programme.

Risks

  • Transparencylimited

    Transparency and explainability are set as a principle («when feasible and appropriate»), and the AI procedure mentions disclosure practices, without their implementation being evidenced (S01, S17).

    Transparency and explainability are set as a principle («when feasible and appropriate»), and the AI procedure mentions disclosure practices, without their implementation being evidenced (S01, S17). The only concrete disclosure is in the privacy notice, which states that AI tools process personal data and are used in marketing analysis (S19). For its own models and those provided to third parties (TuneLab, LillyPod models, narrative automation) there are no model cards, performance metrics, limits or training data information (S15, S13, S14). Hence limited, at the level of principle.

  • Risk area

    AI in clinical trials and regulatory documents (recruitment, patient narratives)

  • Risk area

    AI in manufacturing: drug quality and supply

  • Risk area

    Processing of sensitive health data with AI, for example on LillyDirect

  • No serious controversy recorded.

What lies behind the assessment

Research of 3 November 2026
44searches
38pages and documents read
13primary documents
1controversies checked
6open points, named openly
The full research: pillars, evidence, controversies and open points
AI Footprint · Adopter · As of 3 November 2026
Eli Lilly and CoOverall rating: solid

Eli Lilly documents board oversight of AI, a group-wide approval procedure and a concrete information security programme. Figures, external audits and information on the limits of its own models are largely missing.

Safety

40 %
limitedsolidstrong

A concrete cyber programme is documented, AI validation only as self-description.

  • +Cyber programme based on NIST CSF with external audits Source ↗
  • +TuneLab transmits only encrypted model updates Source ↗
  • –No published validation results for its own AI
  • –Law firm examines data sharing via tracking pixels Source ↗
All sources for this pillar (14)

Transparency

20 %
limitedsolidstrong

Transparency is set as a principle, but model information is missing.

  • +Principle «Transparent and Explainable» set out Source ↗
  • +Privacy notice mentions AI in processing personal data Source ↗
  • –No model cards or performance metrics for TuneLab Source ↗
  • –No labelling of AI-generated content documented
All sources for this pillar (7)
What is missing for “strong”

These steps are in the company’s own hands.

1Responsibility
Measure implementation and have it audited

Lilly should publish metrics on reviewed AI applications and training and have its AI management externally audited.

2Safety
Disclose AI validation

Lilly should publish validation and test results for AI in trials, regulatory filings and manufacturing.

3Transparency
Publish model cards and limits

Lilly should provide model cards with performance, limits and training data for TuneLab and its own models.

Context: 101 companies assessed

Distribution of overall ratings, no ranking
strong
none yet
solid
← Eli Lilly and Co is one of 35
limited

No company reaches “strong” today. Disclosure on how companies handle AI is still young across the market.

Controversies
1 1 minor

No deduction for controversies.

Largest risk area
AI in trials and regulatory filings

AI helps select trial participants and drafts patient narratives, but no validation results have been published for this.

How thoroughly assessed
31 Evidence

13 primary documents read, 44 searches.

Read the full reasoning and all sources
Eli Lilly and Co · Full reasoning

AI oversight and approval procedure documented, but little on the limits of the models

Overall rating “solid”. No deduction for controversies. The superscript numbers link directly to the source.

1 · Responsibility

solidWeight 40%

Lilly documents oversight, responsible executives and an approval procedure for AI, but no metrics and no external audit.

What is documented
  • According to the 2026 proxy statement the board oversees AI and receives regular updates from management1 2 3
  • The audit committee oversees AI-related risks, the science and technology committee AI in research4 1
  • The procedure «Using AI Responsibly» requires prior approval of new AI applications and risk impact assessments4
  • Supplier contracts contain AI quality clauses; approved AI products are on a curated list4
  • Since 2024 a Chief AI Officer has been responsible for AI strategy across all functions5
The case against
Implementation not documented
  • No metrics on reviewed use cases, training or bias audits
  • No external audit or certification of AI management found
  • A formal classification of AI risks is not described4
Grievance channels
  • For AI concerns there is only the general reporting line «Speak Up at Lilly»9
Sources for Responsibility (10)
  1. Eli Lilly and Company (SEC EDGAR): Definitive Proxy Statement (DEF 14A) 2026 · 17 March 2026 · primary source
  2. Eli Lilly and Company (SEC EDGAR): Definitive Proxy Statement (DEF 14A) 2025 · 21 March 2025 · primary source
  3. Eli Lilly and Company (SEC EDGAR): Definitive Proxy Statement (DEF 14A) 2024 · 22 March 2024 · primary source
  4. Eli Lilly and Company (sustainability.lilly.com): Use of AI (Impact Areas) · 1 July 2026 · primary source
  5. Eli Lilly and Company (Investor Relations): Lilly appoints Thomas J. Fuchs as company's first Chief AI Officer · 8 October 2024 · primary source
  6. Eli Lilly and Company (SEC EDGAR): Form 10-K for the fiscal year ended December 31, 2025 · 12 February 2026 · primary source
  7. Purdue University, Daniels School of Business: Lilly's AI use cases · 21 January 2025 · secondary source
  8. Recruiter.com (Eli Lilly job posting): Senior Director of AI Quality Assurance · 3 November 2026 · secondary source
  9. Eli Lilly and Company (lilly.com): Ethics & Compliance · 3 November 2026 · primary source
  10. Eli Lilly and Company: Global Privacy Notice – United States · 14 October 2025 · primary source

2 · Safety

solidWeight 40%

The cybersecurity programme in the 10-K is concrete; Lilly describes AI-specific testing only itself.

What is documented
  • Item 1C describes a programme based on NIST CSF with external auditors, maturity assessments, threat simulations and an incident response playbook6
  • The audit committee meets the CIDO, CISO and Chief Privacy Officer; suppliers are reviewed and contractually bound6 7
  • With TuneLab the data stay with the participants; only encrypted model updates are transmitted8
  • According to reports the supercomputer runs on premises and disconnected from the network, with logging and a model registry1 2
  • The UK data protection authority holds no information on self-reported data breaches by Lilly UK9
The case against
AI testing not evidenced
  • No published validation or red-teaming results for Lilly's AI
  • Patient narratives for trial reports are generated automatically, with shortened human review5
  • According to a conference report the model inventory and monitoring are still being built2
Patient data
  • A law firm is examining whether tracking pixels on LillyDirect share health data; a lawsuit is not documented14
  • The privacy notice states that sensitive personal data may be sold13
Sources for Safety (14)
  1. Eli Lilly and Company (lilly.com): New supercomputer could change future medicine · 26 February 2026 · secondary source
  2. Constellation Research (Larry Dignan): Eli Lilly: Lessons from running an AI factory · 1 October 2026 · secondary source
  3. Purdue University, Daniels School of Business: Lilly's AI use cases · 21 January 2025 · secondary source
  4. Recruiter.com (Eli Lilly job posting): Senior Director of AI Quality Assurance · 3 November 2026 · secondary source
  5. Yseop: Eli Lilly case study: content automation · 13 June 2023 · secondary source
  6. Board Cybersecurity (reproduced from Eli Lilly's 10-K): ELI LILLY & Co 10-K Item 1C. Cybersecurity – 2026-02-12 · 12 February 2026 · primary source
  7. Board Cybersecurity (reproduced from Eli Lilly's 10-K): ELI LILLY & Co 10-K Cybersecurity (Tracker) – 2026-02-12 · 12 February 2026 · primary source
  8. Revvity Signals: Lilly TuneLab-at-Revvity Federated Learning Program (Information Sheet) · 1 July 2026 · primary source
  9. Information Commissioner's Office (UK): Disclosure log IC-369751-M1Y5 · 18 March 2025 · primary source
  10. BioPharma Dive: Eli Lilly offers biotechs AI models via TuneLab · 9 September 2025 · secondary source
  11. Drug Discovery & Development: Lilly launches TuneLab, sharing AI drug discovery models with biotechs · 11 September 2025 · secondary source
  12. Eli Lilly and Company (sustainability.lilly.com): Use of AI (Impact Areas) · 1 July 2026 · primary source
  13. Eli Lilly and Company: Global Privacy Notice – United States · 14 October 2025 · primary source
  14. Chimicles Schwartz Kriner & Donaldson-Smith LLP: Are Drug Companies and Wellness Companies Sharing Your Health Data? – LillyDirect · 4 December 2025 · secondary source

3 · Transparency

limitedWeight 20%

Only the use of AI with personal data is concretely disclosed; model cards and limits are missing.

What is documented
  • The principle «Transparent and Explainable» requires explanations of results «when feasible and appropriate»2
  • The privacy notice discloses that AI tools process personal data and are used in marketing analysis1
  • Model types and data volume are roughly described for TuneLab4 5
The case against
Models and limits
  • Model cards, performance metrics, limits and training data information are missing for own models and those provided to third parties4 5 6
  • No AI transparency report and no rules on labelling towards patients and professionals
Sources for Transparency (7)
  1. Eli Lilly and Company: Global Privacy Notice – United States · 14 October 2025 · primary source
  2. Eli Lilly and Company (sustainability.lilly.com): Use of AI (Impact Areas) · 1 July 2026 · primary source
  3. Constellation Research (Larry Dignan): Eli Lilly: Lessons from running an AI factory · 1 October 2026 · secondary source
  4. Revvity Signals: Lilly TuneLab-at-Revvity Federated Learning Program (Information Sheet) · 1 July 2026 · primary source
  5. BioPharma Dive: Eli Lilly offers biotechs AI models via TuneLab · 9 September 2025 · secondary source
  6. Drug Discovery & Development: Lilly launches TuneLab, sharing AI drug discovery models with biotechs · 11 September 2025 · secondary source
  7. Fierce Biotech: Eli Lilly invites biotechs to use its new AI platform to help develop their own drugs · 9 September 2025 · secondary source

4 · Why the harm rule does not apply

The harm rule does not apply: no AI-related harm, decision or settlement is documented for the period; the law firm inquiry into LillyDirect is a minor controversy without a documented lawsuit.

5 · Controversies (1)

6 · What remains open

  • The AI risk factor in the 2025 10-K and Item 1C in the original were not read.
  • How many AI applications were reviewed, with which results, training rates and bias audits?
  • Is there an external audit or certification of AI management?
  • What validation results and limits do own models and those provided to third parties have?
  • The «U.S. Principles on AI» could not be retrieved.
  • How will the inquiry into tracking pixels on LillyDirect end?

7 · How it was assessed

Cut-off date: 3 November 2026 · 44 searches, 38 fetches.

Primary documents read (13)
  • Form 10-K FY2025 (Forward-Looking Statements, Item 1, part of Item 1A)
  • Form 10-K FY2025 Item 1C (reproduced via board-cybersecurity.com)
  • Proxy Statements 2026, 2025 and 2024 (AI sections, board oversight, agenda items)
  • Form 10-Q Q2 2026 and Q1 2025 (Forward-Looking Statements, financial section)
  • Use of AI (impact page, as at 2026-07-01)
  • Global Privacy Notice – United States (2025-10-14)
  • Ethics & Compliance (Red Book, Speak Up at Lilly)
  • Position Statements (AI entry)
  • Press releases: Chief AI Officer (2024-10-08) and NVIDIA Supercomputer (2025-10-28)
  • TuneLab-at-Revvity Federated Learning Program (July 2026)
  • FDA Warning Letter MARCS-CMS 716475
  • Complaint: State of Texas ex rel. Health Choice Alliance v. Eli Lilly (2025-08-11)
  • ICO Disclosure Log IC-369751-M1Y5

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0

We assess documented practice in dealing with AI; this is not an investment recommendation. Three pillars, weights 40/40/20, harm rule.

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0. Documented observations from public sources, no investment recommendation.

Important Notice. This material is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any financial instrument, nor does it constitute investment advice or a recommendation. The GI 100 Index is a rules-based strategy index of Globalance Bank. Investments involve risk, including the loss of capital invested. The final product documents (including FinSA) shall prevail in all cases.

Your company? Information on inclusion in the GI 100 Index →

What comes next